- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01367600
Open-Label Treatment Extension of Protocol MNTX 301
November 26, 2019 updated by: Bausch Health Americas, Inc.
A Three-Month Open-Label Treatment Extension of Protocol MNTX 301
This study is an open-label extension allowing patients who have completed Protocol MNTX 301 to continue to receive SC MNTX.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
27
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
New York
-
Tarrytown, New York, United States, 10591
- Progenics Pharmaceuticals
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Completion of protocol MNTX 301; Double-Blind Treatment and Open-Label Treatment
- Negative pregnancy test
Exclusion Criteria:
- Women who are pregnant and/or nursing
- Any concurrent experimental drug therapy
- Evidence of fecal impaction
- Clinically significant active diverticular disease
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Arm 1
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of patients with adverse events
Time Frame: 3 months
|
To provide access to continued treatment with MNTX administered SC, to patients who completed Progenics' MNTX 301.
|
3 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change from baseline in pain scores
Time Frame: 3 months
|
To provide access to continued treatment with MNTX administered SC, to patients who completed Progenics' MNTX 301.
|
3 months
|
Number of patients with opioid withdrawal symptoms
Time Frame: 3 months
|
To provide access to continued treatment with MNTX administered SC, to patients who completed Progenics' MNTX 301.
|
3 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
February 1, 2003
Primary Completion (Actual)
February 1, 2005
Study Completion (Actual)
February 1, 2005
Study Registration Dates
First Submitted
May 27, 2011
First Submitted That Met QC Criteria
June 6, 2011
First Posted (Estimate)
June 7, 2011
Study Record Updates
Last Update Posted (Actual)
November 27, 2019
Last Update Submitted That Met QC Criteria
November 26, 2019
Last Verified
November 1, 2019
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- MNTX 301EXT
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Terminal Illness
-
University of ZurichRecruitingTerminal Illness | Terminal CancerSwitzerland
-
Ersta Sköndal University CollegeRecruitingIllness TerminalSweden
-
University College, LondonImperial College London; Brunel University; Marie Curie Hospice, Belfast; Hull...Completed
-
Ersta Sköndal University CollegeForteRecruiting
-
Bausch Health Americas, Inc.Completed
-
National Cancer Center, KoreaCompletedTerminal IllnessKorea, Republic of
-
Yvan Beaussant, MD, MSciHeffter Research Institute; Usona Institute; Oppenheimer Family Psychosocial... and other collaboratorsActive, not recruitingTerminal Illness | Psychotherapy | Psilocybin | Hospice | Demoralization | Cancer-related Problem/Condition | Terminal Cancer | Cancer TerminalUnited States
-
University College, LondonRadboud University Medical Center; University of Bologna; Imperial College London and other collaboratorsCompletedPalliative Care | Terminal IllnessNetherlands, Belgium, Italy, Switzerland, Germany, United Kingdom
-
Northumbria Healthcare NHS Foundation TrustCompletedPalliative Care | Terminal Illness | Hospice CareUnited Kingdom
-
The Ketamine Research FoundationNot yet recruiting
Clinical Trials on SC Methylnaltrexone (MNTX)
-
Bausch Health Americas, Inc.CompletedHealthy SubjectsUnited States
-
University Medicine GreifswaldCompleted
-
Bausch Health Americas, Inc.CompletedLiver DysfunctionUnited States
-
Bausch Health Americas, Inc.Completed
-
Bausch Health Americas, Inc.Completed
-
Bausch Health Americas, Inc.CompletedRenal ImpairmentUnited States
-
Bausch Health Americas, Inc.CompletedHealthy Male VolunteersUnited States
-
Bausch Health Americas, Inc.Wyeth is now a wholly owned subsidiary of PfizerCompletedAdvance Illness Patients With OICUnited States
-
Bausch Health Americas, Inc.CompletedPostoperative IleusUnited States
-
Bausch Health Americas, Inc.CompletedNormal VolunteersUnited States